Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anneke Kwee is active.

Publication


Featured researches published by Anneke Kwee.


BMJ | 2010

Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT)

Kim Boers; Sylvia M. C. Vijgen; Denise Bijlenga; J.A. van der Post; Dick J. Bekedam; Anneke Kwee; P.C.M. Van Der Salm; M.G. van Pampus; Marc Spaanderman; K de Boer; Johannes J. Duvekot; Henk A. Bremer; Tom H.M. Hasaart; Friso M.C. Delemarre; K.W. Bloemenkamp; C.A. van Meir; Christine Willekes; Ella Wijnen; Monique Rijken; S. le Cessie; Frans J.M.E. Roumen; Jim Thornton; J. M. M. van Lith; Ben Willem J. Mol; Sicco Scherjon

Objective To compare the effect of induction of labour with a policy of expectant monitoring for intrauterine growth restriction near term. Design Multicentre randomised equivalence trial (the Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)). Setting Eight academic and 44 non-academic hospitals in the Netherlands between November 2004 and November 2008. Participants Pregnant women who had a singleton pregnancy beyond 36+0 weeks’ gestation with suspected intrauterine growth restriction. Interventions Induction of labour or expectant monitoring. Main outcome measures The primary outcome was a composite measure of adverse neonatal outcome, defined as death before hospital discharge, five minute Apgar score of less than 7, umbilical artery pH of less than 7.05, or admission to the intensive care unit. Operative delivery (vaginal instrumental delivery or caesarean section) was a secondary outcome. Analysis was by intention to treat, with confidence intervals calculated for the differences in percentages or means. Results 321 pregnant women were randomly allocated to induction and 329 to expectant monitoring. Induction group infants were delivered 10 days earlier (mean difference −9.9 days, 95% CI −11.3 to −8.6) and weighed 130 g less (mean difference −130 g, 95% CI −188 g to −71 g) than babies in the expectant monitoring group. A total of 17 (5.3%) infants in the induction group experienced the composite adverse neonatal outcome, compared with 20 (6.1%) in the expectant monitoring group (difference −0.8%, 95% CI −4.3% to 3.2%). Caesarean sections were performed on 45 (14.0%) mothers in the induction group and 45 (13.7%) in the expectant monitoring group (difference 0.3%, 95% CI −5.0% to 5.6%). Conclusions In women with suspected intrauterine growth restriction at term, we found no important differences in adverse outcomes between induction of labour and expectant monitoring. Patients who are keen on non-intervention can safely choose expectant management with intensive maternal and fetal monitoring; however, it is rational to choose induction to prevent possible neonatal morbidity and stillbirth. Trial registration International Standard Randomised Controlled Trial number ISRCTN10363217.


BMJ | 2010

Perinatal mortality and severe morbidity in low and high risk term pregnancies in the Netherlands: prospective cohort study

Annemieke C. C. Evers; Hens A. A. Brouwers; Chantal W.P.M. Hukkelhoven; Peter G. J. Nikkels; Janine Boon; Anneke van Egmond-Linden; Jacqueline Hillegersberg; Yvette S. Snuif; Sietske Sterken-Hooisma; Hein W. Bruinse; Anneke Kwee

Objective To compare incidences of perinatal mortality and severe perinatal morbidity between low risk term pregnancies supervised in primary care by a midwife and high risk pregnancies supervised in secondary care by an obstetrician. Design Prospective cohort study using aggregated data from a national perinatal register. Setting Catchment area of the neonatal intensive care unit (NICU) of the University Medical Center in Utrecht, a region in the centre of the Netherlands covering 13% of the Dutch population. Participants Pregnant women at 37 weeks’ gestation or later with a singleton or twin pregnancy without congenital malformations. Main outcome measures Perinatal death (antepartum, intrapartum, and neonatal) or admission to a level 3 NICU. Results During the study period 37 735 normally formed infants were delivered at 37 weeks’ gestation or later. Sixty antepartum stillbirths (1.59 (95% confidence interval 1.19 to 1.99) per 1000 babies delivered), 22 intrapartum stillbirths (0.58 (0.34 to 0.83) per 1000 babies delivered), and 210 NICU admissions (5.58 (4.83 to 6.33) per 1000 live births) occurred, of which 17 neonates died (0.45 (0.24 to 0.67) per 1000 live births). The overall perinatal death rate was 2.62 (2.11 to 3.14) per 1000 babies delivered and was significantly higher for nulliparous women compared with multiparous women (relative risk 1.65, 95% confidence interval 1.11 to 2.45). Infants of pregnant women at low risk whose labour started in primary care under the supervision of a midwife had a significant higher risk of delivery related perinatal death than did infants of pregnant women at high risk whose labour started in secondary care under the supervision of an obstetrician (relative risk 2.33, 1.12 to 4.83). NICU admission rates did not differ between pregnancies supervised by a midwife and those supervised by an obstetrician. Infants of women who were referred by a midwife to an obstetrician during labour had a 3.66 times higher risk of delivery related perinatal death than did infants of women who started labour supervised by an obstetrician (relative risk 3.66, 1.58 to 8.46) and a 2.5-fold higher risk of NICU admission (2.51, 1.87 to 3.37). Conclusions Infants of pregnant women at low risk whose labour started in primary care under the supervision of a midwife in the Netherlands had a higher risk of delivery related perinatal death and the same risk of admission to the NICU compared with infants of pregnant women at high risk whose labour started in secondary care under the supervision of an obstetrician. An important limitation of the study is that aggregated data of a large birth registry database were used and adjustment for confounders and clustering was not possible. However, the findings are unexpected and the obstetric care system of the Netherlands needs further evaluation.


Obstetrics & Gynecology | 2010

Cardiotocography plus ST analysis of fetal electrocardiogram compared with cardiotocography only for intrapartum monitoring: a randomized controlled trial

Michelle E.M.H. Westerhuis; Gerard H. A. Visser; Karel G.M. Moons; Nicolaas P.A. Zuithoff; Ben Willem J. Mol; Anneke Kwee

OBJECTIVE: To estimate the effectiveness of intrapartum fetal monitoring by cardiotocography plus ST analysis using a strict protocol for performance of fetal blood sampling. METHODS: We performed a multicenter randomized trial among laboring women with a high-risk singleton pregnancy in cephalic presentation beyond 36 weeks of gestation. Participants were assigned to monitoring by cardiotocography with ST analysis (index) or cardiotocography only (control). Primary outcome was metabolic acidosis, defined as an umbilical cord artery pH below 7.05 combined with a base deficit calculated in the extracellular fluid compartment above 12 mmol/L. Secondary outcomes were metabolic acidosis in blood, operative deliveries, Apgar scores, neonatal admissions, and hypoxic–ischemic encephalopathy. RESULTS: We randomly assigned 5,681 women to the two groups (2,832 index, 2,849 control). The fetal blood sampling rate was 10.6% in the index compared with 20.4% in the control group (relative risk 0.52; 95% [CI] 0.46–0.59). The primary outcome occurred 0.7% in the index compared with 1.1% in the control group (relative risk 0.70; 95% CI 0.38–1.28; number needed to treat 252). Using metabolic acidosis calculated in blood, these rates were 1.6% and 2.6%, respectively (relative risk 0.63; 95% CI 0.42–0.94; number needed to treat 100). The number of operative deliveries, low Apgar scores, neonatal admissions, and newborns with hypoxic–ischemic encephalopathy was comparable in both groups. CONCLUSION: Intrapartum monitoring by cardiotocography combined with ST analysis does not significantly reduce the incidence of metabolic acidosis calculated in the extracellular fluid compartment. It does reduce the incidence of metabolic acidosis calculated in blood and the need for fetal blood sampling without affecting the Apgar score, neonatal admissions, hypoxic–ischemic encephalopathy, or operative deliveries. CLINICAL TRIAL REGISTRATION: ISRCTN Register, www.isrctn.org, ISRCTN95732366. LEVEL OF EVIDENCE: I


British Journal of Obstetrics and Gynaecology | 2015

Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis

Ewoud Schuit; Sarah J. Stock; Line Rode; Dwight J. Rouse; Arianne C. Lim; Jane E. Norman; Anwar H. Nassar; Vicente Serra; C. A. Combs; Christophe Vayssiere; M. M. Aboulghar; S. Wood; E. Çetingöz; C. M. Briery; E. B. Fonseca; K. Worda; Ann Tabor; Elizabeth Thom; Steve N. Caritis; Johnny Awwad; Ihab M. Usta; Alfredo Perales; J. Meseguer; K. Maurel; Thomas J. Garite; M. A. Aboulghar; Y. M. Amin; Sue Ross; C. Cam; A. Karateke

In twin pregnancies, the rates of adverse perinatal outcome and subsequent long‐term morbidity are substantial, and mainly result from preterm birth (PTB).


Obstetrics & Gynecology | 2012

17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.

Arianne C. Lim; Ewoud Schuit; Kitty W. M. Bloemenkamp; Rob E. Bernardus; Johannes J. Duvekot; Jan Jaap Erwich; Jim van Eyck; Rolf H.H. Groenwold; Tom H.M. Hasaart; Piet Hummel; Michael M. Kars; Anneke Kwee; Charlotte van Oirschot; Marielle van Pampus; Dimitri Papatsonis; Martina Porath; Marc Spaanderman; Christine Willekes; Janine Wilpshaar; Ben Willem J. Mol; Hein W. Bruinse

OBJECTIVE: To estimate whether administration of 17&agr;-hydroxyprogesterone caproate can prevent neonatal morbidity in multiple pregnancies by reducing the preterm birth rate. METHODS: We conducted a multicenter, double-blind, placebo-controlled randomized trial in 55 obstetric clinics in the Netherlands. Women with a multiple pregnancy were randomized to weekly injections of either 250 mg 17&agr;-hydroxyprogesterone caproate or placebo, starting between 16 and 20 weeks of gestation and continuing until 36 weeks of gestation. The main outcome measure was adverse neonatal outcome. Secondary outcome measures were gestational age at delivery and delivery before 28, 32, and 37 weeks of gestation. RESULTS: We randomized 671 women. A composite measure of adverse neonatal outcome was present in 110 children (16%) born to mothers in the 17&agr;-hydroxyprogesterone caproate group, and in 80 children (12%) of mothers in the placebo group (relative risk [RR] 1.34; 95% confidence interval [CI] 0.95–1.89). The mean gestational age at delivery was 35.4 weeks for the 17&agr;-hydroxyprogesterone caproate group and 35.7 weeks for the placebo group (P=.32). Treatment with 17&agr;-hydroxyprogesterone caproate did not reduce the delivery rate before 28 weeks (6% in the 17&agr;-hydroxyprogesterone caproate group compared with 5% in the placebo group, RR 1.04; 95% CI 0.56–1.94), 32 weeks (14% compared with 10%, RR 1.37; 95% CI 0.91–2.05), or 37 weeks of gestation (55% compared with 50%, RR 1.11; 95% CI 0.97–1.28). CONCLUSION: 17&agr;-hydroxyprogesterone caproate does not prevent neonatal morbidity or preterm birth in multiple pregnancies. CLINICAL TRIAL REGISTRATION: ISRCTN Register, www.isrctn.org, ISRCTN40512715. LEVEL OF EVIDENCE: I


PLOS Medicine | 2012

Induction of Labor versus Expectant Management in Women with Preterm Prelabor Rupture of Membranes between 34 and 37 Weeks: A Randomized Controlled Trial

David van der Ham; Sylvia M. C. Vijgen; Jan G. Nijhuis; Johannes J. van Beek; Brent C. Opmeer; Antonius L.M. Mulder; Rob Moonen; Mariet Groenewout; Marielle van Pampus; Gerald Mantel; Kitty W. M. Bloemenkamp; Wim van Wijngaarden; Marko Sikkema; Monique C. Haak; Paula Pernet; Martina Porath; Jan Molkenboer; Simone Kuppens; Anneke Kwee; Michael Kars; Mallory Woiski; Martin Weinans; Hajo I. J. Wildschut; Bettina M.C. Akerboom; Ben Willem J. Mol; Christine Willekes

In a randomized controlled trial David van der Ham and colleagues investigate induction of labor versus expectant management for women with preterm prelabor rupture of membranes.


JAMA | 2013

Effect of Maintenance Tocolysis With Nifedipine in Threatened Preterm Labor on Perinatal Outcomes A Randomized Controlled Trial

Carolien Roos; Marc Spaanderman; Ewoud Schuit; Kitty W. M. Bloemenkamp; Antoinette C. Bolte; Jérôme Cornette; Johannes J. Duvekot; Jim van Eyck; Maureen Franssen; Christianne J.M. de Groot; Joke H. Kok; Anneke Kwee; Ashley Merien; Bas Nij Bijvank; Brent C. Opmeer; Martijn A. Oudijk; Marielle van Pampus; Dimitri Papatsonis; Martina Porath; Hubertina C. J. Scheepers; Sicco Scherjon; Krystyna M. Sollie; Sylvia M. C. Vijgen; Christine Willekes; Ben Willem J. Mol; Joris A. M. van der Post; Fred K. Lotgering

IMPORTANCE In threatened preterm labor, maintenance tocolysis with nifedipine, after an initial course of tocolysis and corticosteroids for 48 hours, may improve perinatal outcome. OBJECTIVE To determine whether maintenance tocolysis with nifedipine will reduce adverse perinatal outcomes due to premature birth. DESIGN, SETTING, AND PARTICIPANTS APOSTEL-II (Assessment of Perinatal Outcome with Sustained Tocolysis in Early Labor) is a double-blind, placebo-controlled trial performed in 11 perinatal units including all tertiary centers in The Netherlands. From June 2008 to February 2010, women with threatened preterm labor between 26 weeks (plus 0 days) and 32 weeks (plus 2 days) gestation, who had not delivered after 48 hours of tocolysis and a completed course of corticosteroids, were enrolled. Surviving infants were followed up until 6 months after birth (ended August 2010). INTERVENTION Randomization assigned 406 women to maintenance tocolysis with nifedipine orally (80 mg/d; n = 201) or placebo (n = 205) for 12 days. Assigned treatment was masked from investigators, participants, clinicians, and research nurses. MAIN OUTCOME MEASURES Primary outcome was a composite of adverse perinatal outcomes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage >grade 2, periventricular leukomalacia >grade 1, or necrotizing enterocolitis). Analyses were completed on an intention-to-treat basis. RESULTS Mean (SD) gestational age at randomization was 29.2 (1.7) weeks for both groups. Adverse perinatal outcome was not significantly different between groups: 11.9% (24/201; 95% CI, 7.5%-16.4%) for nifedipine vs 13.7% (28/205; 95% CI, 9.0%-18.4%) for placebo (relative risk, 0.87; 95% CI, 0.53-1.45). CONCLUSIONS AND RELEVANCE In patients with threatened preterm labor, nifedipine-maintained tocolysis did not result in a statistically significant reduction in adverse perinatal outcomes when compared with placebo. Although the lower than anticipated rate of adverse perinatal outcomes in the control group indicates that a benefit of nifedipine cannot completely be excluded, its use for maintenance tocolysis does not appear beneficial at this time. TRIAL REGISTRATION trialregister.nl Identifier: NTR1336.


Journal of Maternal-fetal & Neonatal Medicine | 2004

STAN® S21 fetal heart monitor for fetal surveillance during labor: an observational study in 637 patients

Anneke Kwee; Cw van der Hoorn-van den Beld; J Veerman; Ahs Dekkers; G. H. A. Visser

Objective: To assess the value of the STAN® fetal heart monitor for intrapartum fetal monitoring using cardiotocography (CTG) and fetal electrocardiography (ECG). Design: Prospective observational study. Material and methods: Between August 2000 and November 2002, 637 high-risk labors were monitored using a STAN® S21 fetal heart monitor, providing CTG plus automatic ST analysis of the fetal ECG. Guidelines with recommendations about when to intervene were available. During the study period labor-ward personnel were systematically instructed about the (patho)-physiology of asphyxia and CTG and ST changes during labor. Results: Four hundred and forty-nine recordings were available for analysis of outcome in relation to ST changes. In 61 cases, ST changes requiring intervention occurred > 10 min before birth. In 35 (57%) of these cases, umbilical artery blood pH at delivery was < 7.15. Eighteen (4.0%) neonates were born with metabolic acidosis (umbilical artery pH < 7.05 and extracellular base deficit > 12 mmol/l). Significant ST changes (18–31 min before birth) were present in all five cases with pH < 7.00 and in six of the 13 cases with pH of 7.00–7.04 (false-negative rate 1.6%). Neonatal follow-up showed no adverse outcome. One hundred and ninety-two fetal blood samples (121 in the first stage and 71 in the second stage of labor) were taken from 142 women. Fetal scalp blood pH was < 7.15 in ten samples, 7.15–7.19 in 11 samples, 7.20–7.24 in 30 samples and ⩾ 7.25 in 141 samples. ST changes occurred in eight (80%), six (55%), nine (30%) and 15 (11%) of these cases, respectively. In 188 (29.5%) women, outcome could not be analyzed in relation to ST changes because of inadequate recording (time between end of recording and delivery > 20 min or poor signal quality) or the absence of umbilical cord gases. In this group, four (2.1%) neonates with metabolic acidosis were born. In three of these cases the fetal ECG signal was of was poor quality and in one case the recording had ended 60 min before birth. Conclusion: ST changes were present in all five cases with severe metabolic acidosis (umbilical artery pH < 7.00). ST changes occurred in 46% of cases with mild metabolic acidosis. CTG plus ST analysis was more specific in detecting fetal acidemia than CTG alone.


Obstetrics & Gynecology | 2014

Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor

Gert Jan Van Baaren; Jolande Y. Vis; Femke F. Wilms; Martijn A. Oudijk; Anneke Kwee; Martina Porath; Guid Oei; H. C. J. Scheepers; Marc Spaanderman; Kitty Bloemenkamp; M.C. Haak; Antoinette C. Bolte; Caroline J. Bax; Jérôme Cornette; Johannes J. Duvekot; Bas W.A. Nij Bijvanck; Jim van Eyck; Maureen Franssen; Krystyna M. Sollie; Frank Vandenbussche; Mallory Woiski; William A. Grobman; Joris A. M. van der Post; Patrick M M Bossuyt; Brent C. Opmeer; Ben Willem J. Mol

OBJECTIVE: To estimate the performance of combining cervical length measurement with fetal fibronectin testing in predicting delivery in women with symptoms of preterm labor. METHODS: We conducted a prospective nationwide cohort study in all 10 perinatal centers in The Netherlands. Women with symptoms of preterm labor between 24 and 34 weeks of gestation with intact membranes were included. In all women, qualitative fibronectin testing (0.050-microgram/mL cutoff) and cervical length measurement were performed. Logistic regression was used to predict spontaneous preterm delivery within 7 days after testing. A risk less than 5%, corresponding to the risk for women with a cervical length of at least 25 mm, was considered as low risk. RESULTS: Between December 2009 and August 2012, 714 women were enrolled. Fibronectin results and cervical length were available for 665 women, of whom 80 (12%) delivered within 7 days. Women with a cervical length of at least 30 mm or with a cervical length between 15 and 30 mm with a negative fibronectin result were at low risk (less than 5%) of spontaneous delivery within 7 days. Fibronectin testing in case of a cervical length between 15 and 30 mm additionally classified 103 women (15% of the cohort) as low risk and 36 women (5% of the cohort) as high risk. CONCLUSION: Cervical length measurement, combined with fetal fibronectin testing in case of a cervical length between 15 and 30 mm, improves identification of women with a low risk to deliver spontaneously within 7 days. LEVEL OF EVIDENCE: II


British Journal of Obstetrics and Gynaecology | 2009

Inter- and intra-observer agreement of intrapartum ST analysis of the fetal electrocardiogram in women monitored by STAN.

Memh Westerhuis; E. van Horen; Anneke Kwee; I. van der Tweel; G. H. A. Visser; K. G. M. Moons

Objective  The objective of this study was to quantify inter‐ and intra‐observer agreement on classification of the intrapartum cardiotocogram (CTG) and decision to intervene following STAN guidelines.

Collaboration


Dive into the Anneke Kwee's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Johannes J. Duvekot

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Marc Spaanderman

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hubertina C. J. Scheepers

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar

Maureen Franssen

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge